Dare Bioscience, Inc. Recognition of Deferred Revenue
Dare Bioscience, Inc. (DARE) reported Recognition of Deferred Revenue of $507.00 thousand for the 12-month period ending 2016-12-31, per its 10-K/A filed 2017-06-13.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2017-06-13
- Dare Bioscience, Inc. recognition of deferred revenue for fiscal 2016 was $507.00K.
| Period end | Recognition of Deferred Revenue 12 month |
|---|---|
| 2016-12-31 | $507.00K 10-K/A · filed 2017-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |